docetaxel anhydrous and lycopene
docetaxel anhydrous has been researched along with lycopene in 2 studies
Compound Research Comparison
Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (lycopene) | Trials (lycopene) | Recent Studies (post-2010) (lycopene) |
---|---|---|---|---|---|
12,110 | 3,216 | 6,920 | 3,078 | 274 | 1,634 |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Fruehauf, J; Lilly, M; Parmakhtiar, B; Simoneau, AR; Tang, Y; Xie, J; Zi, X | 1 |
Fruehauf, JP; Lilly, M; Uchio, E; Zhuang, E; Zi, X | 1 |
Trials
1 trial(s) available for docetaxel anhydrous and lycopene
Article | Year |
---|---|
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Disease Progression; Docetaxel; Humans; Kallikreins; Lycopene; Male; Middle Aged; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Time Factors | 2021 |
Other Studies
1 other study(ies) available for docetaxel anhydrous and lycopene
Article | Year |
---|---|
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carotenoids; Cell Line, Tumor; Docetaxel; Humans; Lycopene; Male; Mice; Mice, Nude; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids; Xenograft Model Antitumor Assays | 2011 |